Cargando…

Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry

INTRODUCTION: The increased incidence of cutaneous melanoma (CM) and Merkel cell carcinoma (MCC) in patients with hematologic malignancies (HM) is well established. While the risk of CM has been assessed in some subtypes of HM including cutaneous T-cell lymphoma, the incidence in patients with prima...

Descripción completa

Detalles Bibliográficos
Autores principales: Banner, Lauren, Joffe, Daniel, Lee, Emily, Porcu, Pierluigi, Nikbakht, Neda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117954/
https://www.ncbi.nlm.nih.gov/pubmed/37089593
http://dx.doi.org/10.3389/fmed.2023.1110511
_version_ 1785028702368694272
author Banner, Lauren
Joffe, Daniel
Lee, Emily
Porcu, Pierluigi
Nikbakht, Neda
author_facet Banner, Lauren
Joffe, Daniel
Lee, Emily
Porcu, Pierluigi
Nikbakht, Neda
author_sort Banner, Lauren
collection PubMed
description INTRODUCTION: The increased incidence of cutaneous melanoma (CM) and Merkel cell carcinoma (MCC) in patients with hematologic malignancies (HM) is well established. While the risk of CM has been assessed in some subtypes of HM including cutaneous T-cell lymphoma, the incidence in patients with primary cutaneous B-cell lymphoma (PCBCL) has not been interrogated. METHODS: Here we evaluated the standardized incidence ratio (SIR) of CM and MCC in 5,179 PCBCL patients compared to approximately 1.5 billion individuals in the general population using the Surveillance, Epidemiology and End Results (SEER) database. Among patients with PCBCL, we identified subgroups that were at increased risk for CM or MCC as a second primary cancer. RESULTS: We found 36 cases of CM in the PCBCL cohort (SIR, 1.35; 95% CI, 0.94–1.86), among which SIR was significantly elevated for non-Hispanic White patients compared to the general population (SIR, 1.48; 95% CI, 1.03–2.06). Males had a significantly increased risk of developing CM after a diagnosis of PCBCL (SIR, 1.60; 95% CI, 1.10–2.26). We found that males in the age group of 50–59 were at increased risk for CM development (SIR, 3.02; 95% CI, 1.11–6.58). Males were at increased risk of CM 1–5 years after PCBCL diagnosis (SIR, 2.06; 95% CI, 1.18–3.34). Patients were at greater risk of developing MCC within 1 year of diagnosis of PCBCL (SIR, 23.60; 95% CI, 2.86–85.27), particularly in patients who were over the age of 80 (SIR, 46.50; 95% CI, 5.63–167.96). Males aged 60–69 with PCBCL, subtype marginal zone, were also at increased risk for MCC (SIR, 42.71; 95% CI, 1.08–237.99). CONCLUSION: There is an increased incidence of CM in White, middle-aged males within 5 years of diagnosis of PCBCL and an increased risk of MCC in elderly patients within 1 year of PCBCL diagnosis. These data suggest that certain subgroups of patients with PCBCL may require more rigid surveillance for CM and MCC.
format Online
Article
Text
id pubmed-10117954
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101179542023-04-21 Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry Banner, Lauren Joffe, Daniel Lee, Emily Porcu, Pierluigi Nikbakht, Neda Front Med (Lausanne) Medicine INTRODUCTION: The increased incidence of cutaneous melanoma (CM) and Merkel cell carcinoma (MCC) in patients with hematologic malignancies (HM) is well established. While the risk of CM has been assessed in some subtypes of HM including cutaneous T-cell lymphoma, the incidence in patients with primary cutaneous B-cell lymphoma (PCBCL) has not been interrogated. METHODS: Here we evaluated the standardized incidence ratio (SIR) of CM and MCC in 5,179 PCBCL patients compared to approximately 1.5 billion individuals in the general population using the Surveillance, Epidemiology and End Results (SEER) database. Among patients with PCBCL, we identified subgroups that were at increased risk for CM or MCC as a second primary cancer. RESULTS: We found 36 cases of CM in the PCBCL cohort (SIR, 1.35; 95% CI, 0.94–1.86), among which SIR was significantly elevated for non-Hispanic White patients compared to the general population (SIR, 1.48; 95% CI, 1.03–2.06). Males had a significantly increased risk of developing CM after a diagnosis of PCBCL (SIR, 1.60; 95% CI, 1.10–2.26). We found that males in the age group of 50–59 were at increased risk for CM development (SIR, 3.02; 95% CI, 1.11–6.58). Males were at increased risk of CM 1–5 years after PCBCL diagnosis (SIR, 2.06; 95% CI, 1.18–3.34). Patients were at greater risk of developing MCC within 1 year of diagnosis of PCBCL (SIR, 23.60; 95% CI, 2.86–85.27), particularly in patients who were over the age of 80 (SIR, 46.50; 95% CI, 5.63–167.96). Males aged 60–69 with PCBCL, subtype marginal zone, were also at increased risk for MCC (SIR, 42.71; 95% CI, 1.08–237.99). CONCLUSION: There is an increased incidence of CM in White, middle-aged males within 5 years of diagnosis of PCBCL and an increased risk of MCC in elderly patients within 1 year of PCBCL diagnosis. These data suggest that certain subgroups of patients with PCBCL may require more rigid surveillance for CM and MCC. Frontiers Media S.A. 2023-04-06 /pmc/articles/PMC10117954/ /pubmed/37089593 http://dx.doi.org/10.3389/fmed.2023.1110511 Text en Copyright © 2023 Banner, Joffe, Lee, Porcu and Nikbakht. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Banner, Lauren
Joffe, Daniel
Lee, Emily
Porcu, Pierluigi
Nikbakht, Neda
Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry
title Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry
title_full Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry
title_fullStr Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry
title_full_unstemmed Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry
title_short Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry
title_sort incidence of cutaneous melanoma and merkel cell carcinoma in patients with primary cutaneous b-cell lymphomas: a population study of the seer registry
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117954/
https://www.ncbi.nlm.nih.gov/pubmed/37089593
http://dx.doi.org/10.3389/fmed.2023.1110511
work_keys_str_mv AT bannerlauren incidenceofcutaneousmelanomaandmerkelcellcarcinomainpatientswithprimarycutaneousbcelllymphomasapopulationstudyoftheseerregistry
AT joffedaniel incidenceofcutaneousmelanomaandmerkelcellcarcinomainpatientswithprimarycutaneousbcelllymphomasapopulationstudyoftheseerregistry
AT leeemily incidenceofcutaneousmelanomaandmerkelcellcarcinomainpatientswithprimarycutaneousbcelllymphomasapopulationstudyoftheseerregistry
AT porcupierluigi incidenceofcutaneousmelanomaandmerkelcellcarcinomainpatientswithprimarycutaneousbcelllymphomasapopulationstudyoftheseerregistry
AT nikbakhtneda incidenceofcutaneousmelanomaandmerkelcellcarcinomainpatientswithprimarycutaneousbcelllymphomasapopulationstudyoftheseerregistry